ArticleKidney international reports2023
Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan.
Article in Kidney international reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 3 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue.Journal of clinical apheresis · 2026Guideline
- The 2025 British Society for Rheumatology management recommendations for ANCA-associated vasculitis.Rheumatology (Oxford, England) · 2025Guideline
- Guideline
- Rituximab With or Without Avacopan in ANCA-Associated Vasculitis With Severe Renal Involvement.Kidney international reports · 2026Article
- Advances in the treatment of eosinophilic granulomatosis with polyangiitis.Nature reviews. Rheumatology · 2026Review
- Real-world efficacy and safety of avacopan in ANCA-associated vasculitis: a retrospective comparative study.RMD open · 2026Article
- Article
- Advances in the Diagnosis, Treatment and Prognosis of ANCA-Associated Glomerulonephritis.Medicina (Kaunas, Lithuania) · 2026Review
- Complement Dysregulation in Kidney Diseases: Mechanisms, Biomarkers, and Emerging Targeted Therapies.International journal of molecular sciences · 2026Review
- Systematic Review of Efficacy and Safety of Avacopan in Real-World Clinical Practice.Kidney international reports · 2026Article
- Kidney Outcomes in ANCA-Glomerulonephritis According to Induction Immunosuppression and Histopathology.Kidney international reports · 2026Article
- Longitudinal Trajectories of Kidney Function in Patients with Severe ANCA-Associated Vasculitis.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Avacopan as an add-on therapy in a paediatric patient with new-onset granulomatosis with polyangiitis and acute kidney injury: a case report.Rheumatology (Oxford, England) · 2026Article
- Targeting the complement system in ANCA-associated vasculitis management.Rheumatology (Oxford, England) · 2026Review
- New Anticomplement Drugs in Nephrology: Mechanism and Indication.Kidney & blood pressure research · 2026Review
- Canadian Society of Nephrology Commentary on the Evolving Kidney Disease Improving Global Outcomes Adult Glomerulonephritis Guidelines.Canadian journal of kidney health and disease · 2026Article
- Making use of avacopan in clinical practice.Clinical kidney journal · 2026Review
- Addressing clinical challenges in ANCA-associated vasculitis with real-world evidence.Rheumatology (Oxford, England) · 2026Review
- Combining Treatment and Histopathology: Understanding Kidney Recovery in Severe Antineutrophil Cytoplasmic Autoantibody-Associated Rapidly Progressive Glomerulonephritis.Kidney international reports · 2025Article
- Lupus Nephritis: Unmet Needs and Evolving Solutions.Clinical journal of the American Society of Nephrology : CJASN · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In the 330-patient ADVOCATE trial of avacopan for the treatment of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, in which 81% of patients had renal involvement, estimated glomerular filtration rate (eGFR) increased on average 7.3 ml/min per 1.73 m Methods: eGFR was determined at baseline and over the course of the trial. Changes in eGFR were compared between the 2 treatment groups. Results: In ADVOCATE, 27 of 166 patients (16%) in the avacopan group and 23 of 164 patients (14%) in the prednisone group had a baseline eGFR ≤20 ml/min per 1.73 m Conclusion: Among patients with baseline eGFR ≤20 ml/min per 1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.